Monograph Details
|
|
Dermatological Disorders
> Skin infections (topicals)
|
|
LOTRISONE |
| Manufacturer |
|
Schering Corporation |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Steroid + azole antifungal. |
| Generic Name |
|
Betamethasone (as dipropionate) 0.05%, clotrimazole 1%; crm; lotion. |
| Indications |
|
Fungal skin infections. |
| Children |
|
Not recommended. |
| Adults |
|
Apply sparingly twice daily; max 45g (cream), 45mL (lotion) per week. Max 2 wks for t. cruris, t. corporis; 4 wks for t. pedis. |
| Contraindications |
|
Varicella, vaccinia. |
| Precautions |
|
Do not occlude. Use lowest effective dose (esp. in children). Monitor patients regularly. Discontinue steroid if infection persists, worsens or superinfection occurs. Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Irritation, erythema, stinging, folliculitis, hypertrichosis, dermatitis, HPA axis suppression (esp. in children), epidermal and dermal atrophy (esp. in thin-skinned or occluded areas). |
| How Supplied |
Crm—15g, 45g
Lotion—30mL |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
